Attitudes toward disclosure of medication side effects: a nationwide survey of Korean patients, caregivers, and oncologists
Authors:
Open Access
- 13 May 2015
- journal article
- research article
- Published by Wiley in Psycho-Oncology
- Vol. 24 (11) , 1398-1406
Abstract
Background We aimed to compare the views of cancer patients, family caregivers, and oncologists about the disclosure of side effects in respect to their probability of occurrence, severity, and treatment purpose. We also compared attitudes toward potential harm of side effect disclosure, patients' perceived ability to understand the risk of the side effects, and informed decision-making regarding side effects. Methods A national survey was performed with 750 patient–caregiver dyads (75.5% participation rate) recruited by 134 oncologists in 13 cancer centers (93% participation rate). Attitudes toward communication of side effects were assessed in terms of drug purpose, severity of potential complications, and probability of harm. Results Most patients (82.1–87.0%) and caregivers (75.9–81.5%) thought they should be informed of all possible drug side effects regardless of risk, severity, or drug purpose and wanted these risks to be communicated explicitly. Patients and their caregivers believed that detailed explanations of side effects did not harm patients, and further, they believed that patients could understand risks and make treatment decision based on that information. In contrast, oncologists held less positive attitudes toward providing detailed information about drug side effects, especially if they were not severe and if the drugs were designed for supportive care. Conclusion Cancer patients and family members had different perspectives and preferences regarding communication of drug side effects from their oncologists. The data from our study can serve as a guide for oncologists in presenting side effects information to their patients, as well as a basis for physician training. Copyright © 2015 John Wiley & Sons, Ltd.Keywords
Funding Information
- National R&D Program for Cancer Control (1210150)
This publication has 39 references indexed in Scilit:
- Oral Information About Side Effects of Endocrine Therapy for Early Breast Cancer Patients at Initial Consultation and First Follow-Up Visit: An Online SurveyHealth Communication, 2013
- Internet chemotherapy information: impact on patients and health professionalsBritish Journal of Cancer, 2012
- Predictors and outcomes of feeling of insufficient consultation time in cancer care in Korea: results of a nationwide multicenter surveySupportive Care in Cancer, 2011
- The Nocebo Effect and Its Relevance for Clinical PracticePsychosomatic Medicine, 2011
- Information about chemotherapy‐associated cognitive problems contributes to cognitive problems in cancer patientsPsycho-Oncology, 2011
- Placebo and nocebo effects in randomized double‐blind clinical trials of agents for the therapy for fatigue in patients with advanced cancerCancer, 2009
- Which Providers Should Communicate Which Critical Information About a New Medication? Patient, Pharmacist, and Physician PerspectivesJournal of the American Geriatrics Society, 2009
- Potential chemotherapy side effects: What do oncologists tell parents?Pediatric Blood & Cancer, 2008
- Patients' Perceptions of Physician‐Patient Discussions and Adverse Events with Cancer TherapyArchives of Drug Information, 2008
- Doctor’s views on disclosing or withholding information on low risks of complicationJournal of Medical Ethics, 2007